We are pleased to inform that Noile-Immune Biotech, Inc (herein, Noile) announced the initiation of phase I clinical trial of NIB103, which was licensed to Takeda Pharmaceutical Company Limited (“Takeda”) and has been developed as TAK-103. NIB103 is now the third pipeline in a clinical phase equipped with Noile’s PRIME technology.

For more details, please refer to the official news release of Noile below; ​

https://www.noile-immune.com/dcms_media/other/20211224_NIB103_Phase1_News_PR_en.pdf  

Initiation of Phase I Clinical Trial of NIB103/TAK-103 

  We are pleased to announce the initiation of Phase I clinical trial of NIB103, an investigational cell therapy licensed from our company to Takeda Pharmaceutical Company Limited (hereafter Takeda) and designated as TAK-103. 

  NIB103 is a CAR-T cell targeting mesothelin expressed on solid tumors and equipped with “PRIME” (proliferation inducing and migration enhancing), our core technology. Takeda holds the exclusive and global rights to develop and commercialize NIB103. For details of the clinical trial, please refer to the following registration information:

  https://clinicaltrials.gov/ct2/show/NCT05164666

  This is the third clinical trial of the pipeline equipped with our PRIME technology, following NIB102/TAK-102 and NIB101.

  We will continuously promote Research and Development under the collaboration with pharmaceutical companies and research organizations to expand our pipeline utilizing PRIME technology and promote to ensure the delivery of effective therapies for cancer patients who don’t have an effective treatment option at the earliest possible date.

[Explanation of technical words]

PRIME technology: A platform technology to enhance anti-tumor efficacy of immune cell therapies by simultaneous productions of Interleukin-7 and CCL-19. 

CAR-T cells: Chimeric antigen receptor-T cells which express an artificial receptor consisting of single chain antibody against cell-surface tumor antigen and signaling domains important for T cell activation.